The Use of Transcranial Direct Current Stimulation (tDCS) in Adults With Developmental Disabilities
Launched by DR. NAJAT KHALIFA · Jan 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called transcranial Direct Current Stimulation (tDCS) to help reduce aggressive behaviors in adults with developmental disabilities. Aggression can be a common challenge for people in this group, and researchers believe that tDCS, which is a non-invasive way to gently stimulate the brain, could help decrease impulsivity and aggression. The trial is currently looking for participants aged 18 to 64 who have a developmental disability and have shown aggressive behavior in the past month.
To take part in the study, individuals should not have a history of seizures, brain injuries, or certain medical devices like cochlear implants or pacemakers. Participants will receive the tDCS treatment and will be closely monitored to see how it affects their behavior. This trial aims to provide new insights into how we can better support individuals with developmental disabilities in managing aggression, ultimately improving their quality of life. If you're interested or have questions, please reach out to the research team for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-64 years
- • Diagnosis of a developmental disability
- • History of one or more incidents of aggression in the last month
- • Consent to participate in the trial by the individual or their Substitute Decision Maker
- Exclusion Criteria:
- • History of epilepsy or seizures
- • History of acquired brain injury
- • Having metal in the brain/skull, e.g. splinters, fragments or clips
- • Having a cochlear implant
- • Having an implanted neuro-stimulator (e.g. direct brain stimulation, epidural/subdural stimulation, vagal nerve stimulation)
- • History of brain surgery of procedure
- • History of severe adverse reaction to tDCS
- • Having a cardiac pacemaker or intracardiac lines
- • Current alcohol or drug misuse
- • Having a sensitive scalp
About Dr. Najat Khalifa
Dr. Najat Khalifa is a distinguished clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical trial design and implementation, Dr. Khalifa leads initiatives that focus on innovative therapies and evidence-based practices. Her collaborative approach fosters partnerships among healthcare professionals, regulatory bodies, and research institutions, ensuring the highest standards of compliance and ethical conduct in all trials. Dr. Khalifa is dedicated to facilitating groundbreaking studies that contribute to the development of novel treatments and enhance the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingston, Ontario, Canada
Kingston, Ontario, Canada
Patients applied
Trial Officials
Muhammad Ayub, MD
Study Chair
Queen's University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials